On Tuesday, October 31, 2017, the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSRM) Advisory Committee supported, by a vote of 18-Yes to 1-No, with no abstentions, the approval of buprenorphine subcutaneous injection (RBP-6000), submitted by Indivior Pharmaceuticals, Inc. (Indivior), for the treatment of opioid dependence.
Back to All Events
Earlier Event: October 18
Endocrinologic and Metabolic Drugs Advisory Committee
Later Event: November 1
Clinical Laboratory Improvement Advisory Committee